bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

Contributed by: Business Wire

Logo

Tags

Biotechnology

Professional Services

Health

Philanthropy

Pharmaceutical

Other Science

Research

Fund Raising

Genetics

Science

Finance

More Like This

CRISPR-Ready ioGlutamatergic Neurons (Graphic: Business Wire)

bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery

ioMotor Neurons (Photo: Business Wire)

bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)

bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference

Scientists at King's College London and bit.bio Collaborate to Develop Multi-Cell Models of the Human Brain With Optimised Open-Source Protocols for Use by Any Researcher

(Graphic: Business Wire)

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

bit.bio's cell therapy pipeline November 2023 (Graphic: Business Wire)

bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

(Photo: Business Wire)

Merck and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s research